SCYX
SCYNEXIS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.66
−0.27%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.75
From 52W high−58.78%
Volume76331.00
Market cap$36.42M
P/E (TTM)—
P/S (TTM)1.9x
Div yield—
Key dataOct 19, 2026
Open
$3.75
From 52W high
−58.78%
Volume
76331.00
Market cap
$36.42M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.5x
P/E (TTM)
—
RSI (14)
34.9
MomentumView details →
1D Return
−0.27%
YTD Return
−25.30%
SummaryUpdated Jun 1, 2026
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company founded in 1999 and headquartered in Jersey City, New Jersey. The company went public in May 2014 and specializes in developing antifungal treatments, with a particular focus on addressing serious and life-threatening fungal infections. SCYNEXIS has successfully brought its first commercial product, BREXAFEMME, to market and continues to develop its lead compound ibrexafungerp for various fungal indications through clinical trials and strategic partnerships.
Similar companies
Latest newsMore news →
SCYNEXIS announced Phase 1 study results for SCY-770, a novel oral direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD), reporting it was well tolerated with a favorable safety profile in healthy adult participants.14d agoSCYNEXIS Inc signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) worth up to $214 million to develop SCY-247, with an initial base period of approximately $18.5 million for a Phase 2 study.21d agoSCYNEXIS was awarded a contract by BARDA worth up to $214 million in non-dilutive funding to advance development of its second-generation antifungal candidate SCY-247.22d ago